Jafron Biomedical Co., Ltd.

Jafron Biomedical Co., Ltd. is a Chinese manufacturing company specializing in the research, development, production, and sales of biomaterials and high-tech medical devices. Established in 1989 and listed on the Shenzhen Stock Exchange in 2016, Jafron is a prominent provider of blood purification products, utilizing innovative technology to enhance patient care. The company focuses on developing disposable medical devices that are essential in treating conditions such as uremia, poisoning, severe liver disease, autoimmune diseases, and multi-organ failure. The company’s main business lines include a range of blood purification products, such as disposable hemoperfusion cartridges and various adsorption columns, which are widely used in over 6,000 hospitals across China and exported to 98 countries. Jafron has established multiple production bases and research facilities in key locations throughout China, enhancing its operational capacity and market reach. The company aims to create a comprehensive blood purification industry chain that integrates equipment, consumables, and medical services, positioning itself for future growth and innovation in the healthcare sector.

Established in 1989, Jafron Biomedical Co., Ltd. specializes in the R&D, production and sales of biomaterials and high-tech medical devices, and is a listed company with blood purification products as its main business (stock code: 300529). The company's market capitalization ranks among the top of medical equipment listed companies in China, and it has been awarded “Golden Bull Most Valuable Investment Award” and “Top 50 GEM Listed Companies” for 4 consecutive years, and in 2019, it was honored with “Best Shareholder Return Listed Company Award” and “Competitive Enterprise Award” of GEM, and was listed as one of the 2020 Hurun China's Top 100 Private Enterprises in Health industry, and the accumulated tax payment of the company in the recent three years is about 1.2 billion CNY. Jafron has been awarded “Second Prize of National Science and Technology Progress Award”, “First Prize of Guangdong Science and Technology Progress Award” and many other national awards and undertakes several national and provincial technology research and industrialization projects, was approved to set up a national enterprise technology center, academician workstation, postdoctoral research station and other scientific research platforms. The company is one of the first enterprises in China and the second one in Guangdong Province to pass the GMP inspection of medical devices, and its products have obtained CE certification and ISO international quality management system certification, and it has been awarded as Guangdong Province's class A quality credit medical device manufacturer for 12 consecutive years. The original and world-leading hemoperfusion products and many pioneering clinical therapy developed by Jafron such as Direct Blood Adsorption, DPMAS, combined artificial kidney (HD+HP Therapy) and adsorption extracorporeal circulation (CPB+HA380 Therapy), etc., have been introduced into more than 6,000 hospitals in more than 30 provinces in China and exported to more than 90 countries such as Germany, Britain, Italy, etc., which are widely used in uremia, poisoning, severe liver disease, autoimmune disease, multi-organ failure and other fields, and have saved hundreds of thousands of patients every year. After the blood purification research and production base (Jafron Science and Technology Park) was built in 2015, Jafron has been expanding its industrial scale, investing in three production bases in Zhuhai City one after another, and setting up new production and scientific research enterprises in Beijing, Tianjin, Guangzhou, Shenzhen, Hubei and other places to form an industrial layout covering South China, Central China and North China. In the future, Jafron will build a unique blood purification industry chain integrating blood purification equipment, consumables, medicines, insurance, chronic disease management and medical service, realize group, brand and diversified development, and lay a solid foundation for the vision of becoming a “world-class high-tech medical enterprise group”.